Sodium picosulfate in opioid-induced constipation: Results of an open-label, prospective, dose-ranging study

Palliative Medicine

Volumn 20, Issue 4, 2006, Pages 419-423

  Twycross, Robert G ^a   McNamara, Paul ^a   Schuijt, Chris ^b   Kamm, Michael A ^c   Jordan, Chris ^c  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c ST MARK S HOSPITAL   (United Kingdom)

Author keywords

Constipation; Dose ranging; Laxative; Opioid; Sodium picosulfate

Indexed keywords

ENEMA; LAXATIVE; MORPHINE SULFATE; OPIATE; PICOSULFATE SODIUM;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEFECATION; DETERIORATION; DIARRHEA; DOCUMENTATION; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL DESIGN; FEMALE; HUMAN; MALE; MAXIMUM PERMISSIBLE DOSE; SUPPOSITORY; TITRIMETRY; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; CATHARTICS; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NARCOTICS; PICOLINES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33746114622     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1191/0269216306pm1135oa     Document Type: Article

References (15)

1. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63: 649-71.
2. Pappagallo M. Incidence, prevalence and management of opioid bowel dysfunction. Am J Surg 2001; 182: 11S-18.
3. Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 1998; 12: 375-82.
4. Bennett M, Cresswell H. Factors influencing constipation in advanced cancer patients: a prospective study of opioid dose, dantron dose and physical functioning. Palliat Med 2003; 17: 418-22.
5. Mancini IL, Hanson J, Neumann CM, Bruera ED. Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J Palliat Med 2000; 3: 49-56.
6. Kim DH, Hyun SH, Shim SB, Kobashi K. The role of intestinal bacteria in the transformation of sodium picosulphate. Jpn J Pharmacol 1992; 59: 1-5.
7. Herndon CM, Jackson KC, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 2002; 22: 240-50.
8. Twycross RG, Harcourt JMV. The use of laxatives at a palliative care centre. Palliat Med 1991; 5: 27-33.
9. Fallon MT, Hanks GW. Morphine, constipation and performance status in advanced cancer patients. Palliat Med 1999; 13: 159-60.
10. Bouvy ML, Buurma H, Egberts TC. Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention. J Clin Pharm Ther 2002; 27: 107-10.
11. Crowther AG. Management of constipation in terminally ill patients. J Int Med Res 1978; 6: 348-50.
12. Radbruch L, Sabatowski R, Loick G, et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 2000; 14: 111-19.
13. Sykes NP. An investigation into the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996; 10: 135-44.
14. Delaney CP, Weese JL, Hyman NH, et al. Alvimopan Postoperative Ileus Study Group. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005; 48: 1114-25.
15. Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment-randomized clinical trial. J Pain 2005; 6: 184-92.